TNFSF11 and osteoporosis: Moreover, it has been observed that this variant acts as an immunogen triggering the production of anti‐RANKL antibodies, and its use might reduce the risks linked to the abrupt suspension of denosumab use.173,70 The balance achieved among RANK, RANKL, OPG, and LGR4 fine tunes bone resorption in the bone remodeling process, and the pharmacological modulation of this balance has critical therapeutic potential in osteoporosis.172